查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591979

免疫肿瘤检测市场：按适应症、按产品、按技术、按应用划分 - 2025-2030 年全球预测

Immuno Oncology Assays Market by Indication (Bladder Cancer, Colorectal Cancer, Lung Cancer), Product (Consumables, Software), Technology, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年免疫肿瘤检测市场价值为62.6亿美元，预计到2024年将达到72.1亿美元，复合年增长率为15.26%，到2030年将达到169.3亿美元。

免疫肿瘤学测试是重要的诊断工具，用于评估对癌症治疗的免疫反应，并在个人化癌症治疗中发挥重要作用。有必要监测和评估患者对免疫疗法的反应，以确保更有效、更有针对性的癌症治疗并改善治疗结果。这些测定的应用包括识别生物标记、确定肿瘤中的免疫细胞浸润以及优化新的治疗方法。主要最终用户包括实验室、製药公司和临床诊断中心。癌症发病率的上升、免疫疗法的日益普及以及精准医疗的进步正在推动市场成长。此外，政府对癌症研究的资助和生物标记发现的技术创新正在增强市场。最新的潜在商机在于扩大联合治疗和针对各种癌症类型的新生物标记的应用。为了抓住这些机会，建议投资先进技术，例如可以同时分析多种生物标记的多重测定。然而，市场扩张存在一些限制，包括减缓新检测方法引入的监管障碍，以及限制采用率的高成本。此外，免疫反应的复杂性和患者之间的生物变异性也带来了重大挑战。创新和研究的一个主要领域是开发能够提供更高灵敏度和特异性同时具有成本效益的检测方法。与数位技术的集成，例如用于资料分析的人工智慧和改进的实验室自动化，是一个有前途的前沿领域。该市场竞争激烈但又分散，现有参与者众多，而新参与企业的兴趣也与日俱增。持续的研发和策略伙伴关係关係对于促进知识交流和利用前沿发现、塑造免疫肿瘤学诊断的未来模式至关重要。

主要市场统计
基准年[2023] 62.6亿美元
预测年份 [2024] 72.1亿美元
预测年份 [2030] 169.3亿美元
复合年增长率（%） 15.26%

市场动态：揭示快速发展的免疫肿瘤检测市场的关键市场洞察

供需的动态交互作用正在改变免疫肿瘤学检测市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癌症发生率增加以及标靶治疗相对于其他治疗方法的采用
    • 开发生物资讯学工具以增强药物开发过程
    • 医疗支出和医疗保险的增加
  • 市场限制因素
    • 不利的监管和报销情况
  • 市场机会
    • 癌症治疗技术与研发的进步
    • 伴同性诊断的出现
  • 市场挑战
    • 缺乏操作设备的医疗保健专业

波特的五力：驾驭免疫肿瘤检测市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解免疫肿瘤检测市场的外部影响

外部宏观环境因素在塑造免疫肿瘤检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解免疫肿瘤检测市场的竞争格局

免疫肿瘤检测市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵免疫肿瘤检测市场供应商的绩效评估

FPNV定位矩阵是评估免疫肿瘤检测市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了免疫肿瘤检测市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，免疫肿瘤检测市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 与其他治疗方法相比，癌症发生率增加以及标靶治疗的采用
      • 开发生物资讯学工具以增强药物开发过程
      • 医疗费用和医疗保险的增加
    • 抑制因素
      • 不利的监管和报销情况
    • 机会
      • 癌症治疗技术与研发的进步
      • 伴同性诊断的出现
    • 任务
      • 缺乏操作设备的医疗保健专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按适应症分類的免疫肿瘤检测市场

  • 膀胱癌
  • 大肠直肠癌
  • 肺癌
  • 恶性黑色素瘤

第七章免疫肿瘤检测市场：副产品

  • 消耗品
  • 软体

第八章免疫肿瘤学检测市场：依技术分类

  • 流式细胞技术
  • 免疫检测
  • 次世代定序
  • 聚合酵素链锁反应

第九章免疫肿瘤学检测市场：依应用分类

  • 临床诊断
  • 调查

第十章美洲免疫肿瘤检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太免疫肿瘤检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的免疫肿瘤检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • Charles River Laboratories International, Inc.
  • ElsaLys Biotech SA
  • Eurofins DiscoverX Products, LLC
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Merck KGaA
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN GmbH
  • Sartorius AG
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience Corporation
Product Code: MRR-43676CF42882

The Immuno Oncology Assays Market was valued at USD 6.26 billion in 2023, expected to reach USD 7.21 billion in 2024, and is projected to grow at a CAGR of 15.26%, to USD 16.93 billion by 2030.

Immuno-oncology assays are critical diagnostic tools used to assess the immune response to cancer therapies, thus playing a crucial role in personalized cancer treatment. They are necessary for monitoring and evaluating patient responses to immunotherapies, ensuring more effective, targeted cancer treatments with improved outcomes. The application of these assays includes identifying biomarkers, determining immune cell infiltration in tumors, and optimizing novel therapeutic approaches. Predominant end-users include research laboratories, pharmaceutical companies, and clinical diagnostic centers. The growing prevalence of cancer, increasing adoption of immunotherapies, and advancements in precision medicine drive market growth. Furthermore, government funding in cancer research combined with technological innovations in biomarker discovery bolster the market. The latest potential opportunities lie in expanding applications in combination therapies and emerging biomarkers for various cancer types. To seize these opportunities, investment in advanced technologies like multiplexed assays that can concurrently analyze multiple biomarkers is recommended. However, market expansion faces several limitations, including high costs, which can restrain adoption rates, alongside regulatory hurdles that slow the introduction of new assays. Additionally, the complexity of immune responses and the biological variability between patients pose significant challenges. Key areas for innovation and research involve developing assays that offer higher sensitivity and specificity while being cost-effective. Integration with digital technologies, such as AI for data analysis and improved automation in labs, represents a promising frontier. The market is competitive yet fragmented, characterized by the presence of numerous established players and growing interest from new entrants, driving innovation and enhancing product offerings. Continuous R&D and strategic partnerships are essential to foster knowledge exchange and leverage cutting-edge discoveries, shaping the future landscape of immuno-oncology diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 6.26 billion
Estimated Year [2024] USD 7.21 billion
Forecast Year [2030] USD 16.93 billion
CAGR (%) 15.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immuno Oncology Assays Market

The Immuno Oncology Assays Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidences of cancer and adoption of targeted therapy over other treatment options
    • Development of bioinformatic tools enhancing the drug development process
    • Rise in healthcare expenditure and healthcare insurance
  • Market Restraints
    • Unfavorable regulatory and reimbursement scenario
  • Market Opportunities
    • Technological advancement and R&D for the treatment of cancer
    • Emergence of companion diagnostics
  • Market Challenges
    • Lack of healthcare professions for device operation

Porter's Five Forces: A Strategic Tool for Navigating the Immuno Oncology Assays Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immuno Oncology Assays Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immuno Oncology Assays Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immuno Oncology Assays Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immuno Oncology Assays Market

A detailed market share analysis in the Immuno Oncology Assays Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immuno Oncology Assays Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immuno Oncology Assays Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immuno Oncology Assays Market

A strategic analysis of the Immuno Oncology Assays Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immuno Oncology Assays Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, Charles River Laboratories International, Inc., ElsaLys Biotech S.A., Eurofins DiscoverX Products, LLC, HTG Molecular Diagnostics, Inc., Illumina, Inc., Merck KGaA, NanoString Technologies, Inc., NeoGenomics Laboratories, Inc., PerkinElmer, Inc., QIAGEN GmbH, Sartorius AG, Thermo Fisher Scientific, Inc., and Twist Bioscience Corporation.

Market Segmentation & Coverage

This research report categorizes the Immuno Oncology Assays Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Bladder Cancer, Colorectal Cancer, Lung Cancer, and Melanoma.
  • Based on Product, market is studied across Consumables and Software.
  • Based on Technology, market is studied across Flow Cytometry, Immunoassay, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Application, market is studied across Clinical Diagnostics and Research.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of cancer and adoption of targeted therapy over other treatment options
      • 5.1.1.2. Development of bioinformatic tools enhancing the drug development process
      • 5.1.1.3. Rise in healthcare expenditure and healthcare insurance
    • 5.1.2. Restraints
      • 5.1.2.1. Unfavorable regulatory and reimbursement scenario
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement and R&D for the treatment of cancer
      • 5.1.3.2. Emergence of companion diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of healthcare professions for device operation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immuno Oncology Assays Market, by Indication

  • 6.1. Introduction
  • 6.2. Bladder Cancer
  • 6.3. Colorectal Cancer
  • 6.4. Lung Cancer
  • 6.5. Melanoma

7. Immuno Oncology Assays Market, by Product

  • 7.1. Introduction
  • 7.2. Consumables
  • 7.3. Software

8. Immuno Oncology Assays Market, by Technology

  • 8.1. Introduction
  • 8.2. Flow Cytometry
  • 8.3. Immunoassay
  • 8.4. Next-Generation Sequencing
  • 8.5. Polymerase Chain Reaction

9. Immuno Oncology Assays Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Diagnostics
  • 9.3. Research

10. Americas Immuno Oncology Assays Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Immuno Oncology Assays Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Immuno Oncology Assays Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies, Inc.
  • 2. Bio-Rad Laboratories, Inc.
  • 3. BioAgilytix Labs, LLC
  • 4. Charles River Laboratories International, Inc.
  • 5. ElsaLys Biotech S.A.
  • 6. Eurofins DiscoverX Products, LLC
  • 7. HTG Molecular Diagnostics, Inc.
  • 8. Illumina, Inc.
  • 9. Merck KGaA
  • 10. NanoString Technologies, Inc.
  • 11. NeoGenomics Laboratories, Inc.
  • 12. PerkinElmer, Inc.
  • 13. QIAGEN GmbH
  • 14. Sartorius AG
  • 15. Thermo Fisher Scientific, Inc.
  • 16. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. IMMUNO ONCOLOGY ASSAYS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. IMMUNO ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. IMMUNO ONCOLOGY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNO ONCOLOGY ASSAYS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNO ONCOLOGY ASSAYS MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. IMMUNO ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. IMMUNO ONCOLOGY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2023